Han Kyu-Tae, Kim Seungju
Division of Cancer Control and Policy, National Cancer Control Institute, National Cancer Center, Goyang 10408, Korea.
Department of Nursing, College of Nursing, The Catholic University of Korea, Seoul 06591, Korea.
J Clin Med. 2021 May 27;10(11):2361. doi: 10.3390/jcm10112361.
Statins play a role in lowering serum cholesterol and are known to have pleiotropic effects in a variety of diseases, including cancer. Despite the beneficial effects of statins in dyslipidemia patients, the treatment rate for dyslipidemia in Korea remains low, and evidence supporting the continued use of statins is lacking. The purpose of this study was to evaluate the effect of continued statin use and dosage on patient mortality after diagnosis of dyslipidemia and gastrointestinal (GI) cancer.
We used data from the National Health Insurance Sampling (NHIS) cohort to evaluate patients diagnosed with dyslipidemia from 2002 to 2015. A total of 901 GI cancer patients with dyslipidemia and 62,727 non-cancer dyslipidemia patients were included in the study. During the study period, each patient's medication possession ratio (MPR) after diagnosis was evaluated as a measure of continued statin use. Statin dosage was measured based on a defined daily dose (DDD). Finally, we used Cox-proportional hazard ratios to identify associations between the continual use of statins and mortality in patients with dyslipidemia and GI cancer.
In our study, mortality decreased with increasing MPR and reached significance in MPRs exceeding 50% for GI cancer patients and 75% for dyslipidemia patients compared to patients that did not use statins. Moreover, patients with high MPRs had significantly reduced 5-year mortality compared to non-users, and cause-specific mortality analyses revealed that high MPR was associated with decreased colorectal cancer death. We did not find a significant dose-response relationship between statins and mortality.
Our findings suggest that continued statin use after diagnosis is associated with reduced patient mortality. Altogether, these results support the continued use of statins in dyslipidemia patients with and without GI cancer and highlight the importance of patient education by healthcare providers.
他汀类药物在降低血清胆固醇方面发挥作用,并且已知在包括癌症在内的多种疾病中具有多效性作用。尽管他汀类药物对血脂异常患者有有益作用,但韩国血脂异常的治疗率仍然很低,并且缺乏支持继续使用他汀类药物的证据。本研究的目的是评估血脂异常和胃肠道(GI)癌诊断后继续使用他汀类药物及其剂量对患者死亡率的影响。
我们使用了国民健康保险抽样(NHIS)队列的数据来评估2002年至2015年期间被诊断为血脂异常的患者。共有901例患有血脂异常的GI癌患者和62,727例非癌症血脂异常患者纳入本研究。在研究期间,评估每位患者诊断后的药物持有率(MPR)作为继续使用他汀类药物的衡量指标。他汀类药物剂量基于限定日剂量(DDD)进行测量。最后,我们使用Cox比例风险比来确定血脂异常和GI癌患者中继续使用他汀类药物与死亡率之间的关联。
在我们的研究中,死亡率随着MPR的增加而降低,与未使用他汀类药物的患者相比,GI癌患者MPR超过50%以及血脂异常患者MPR超过75%时死亡率具有显著差异。此外,与未使用者相比,MPR高的患者5年死亡率显著降低,病因特异性死亡率分析显示高MPR与结直肠癌死亡减少有关。我们未发现他汀类药物与死亡率之间存在显著的剂量反应关系。
我们的研究结果表明,诊断后继续使用他汀类药物与患者死亡率降低有关。总之,这些结果支持在患有和未患有GI癌的血脂异常患者中继续使用他汀类药物,并强调了医疗保健提供者对患者进行教育的重要性。